search
Back to results

Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery

Primary Purpose

Antibiotic Prophylaxis, Colorectal Surgery

Status
Recruiting
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
Cefuroxime
Sponsored by
University of Leeds
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Antibiotic Prophylaxis focused on measuring Cefuroxime, Antibiotic, Colorectal, Prophylaxis, Surgery

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Undergoing elective colorectal surgery (incision, excision or anastomosis of the large bowel, including anastomosis of small to large bowel) Age >16. Expected duration of surgery > 2hours Creatinine clearance > 40 ml/min Cefuroxime/metronidazole are appropriate antibiotic prophylaxis regimens. Patient capable of giving informed consent Patients undergoing colorectal surgery plus additional surgery e.g. plastic surgery, urological surgery, gynaecological surgery. Exclusion Criteria: Unable to consent Pregnancy Expected duration of surgery <2hours Creatinine clearance <40ml/min Individual level microbiological advice for non-cefuroxime based prophylaxis Cephalosporin allergy Penicillin allergy (hypersensitivity reaction only) Coumarin (warfarin and acenocoumarol) treatment Seizure history or epilepsy Concurrent use of probenecid Current participation in a research project aimed at reducing surgical site infections (SSIs) Antibiotics for treatment of a systemic Gram negative infection within 12 hours of initiation of surgery (Vancomycin, Teicoplanin, Daptomycin, Linezolid, Flucloxacillin. Nitrofurantoin and Clarithromycin would be permissible antibiotics without systemic Gram negative antibiotics). A current diagnosis of infection at the time of study entry. STARR procedures (stapled trans anal resection of the rectum) Weight <30kg or >110kg

Sites / Locations

  • TheUniversity of Birmingham
  • Leeds Teaching HospitalsRecruiting
  • Aneurin Bevan University Health BoardRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Standard treatment

Intervention treatment

Arm Description

Cefuroxime 1.5 grams intravenous Administered in the hour before surgery and then 4 hourly intra-operatively.

Cefuroxime loading dose of 2332mg intravenous Administered in the hour before surgery. Following the loading dose a renal function based dosing will be given as a continuous intravenous infusion throughout surgery, as below. Continuous infusion will continue for up to 6 hours when it will return to 4 hourly dosing of cefuroxime at 1.5 grams intravenously, if required. Creatinine clearance (ml/min) and Cefuroxime:Dose per hour (mg/hr) 40-50ml/min=723mg/hr 50-60ml/min=867mg/hr 60-70ml/min=1011mg/hr 70-80ml/min=1155mg/hr >80ml/min=1227mg/hr

Outcomes

Primary Outcome Measures

Recruitment rates
Rate of recruitment
Retention rates
Rate of retention

Secondary Outcome Measures

Health Care Associated Infection
The number of patients within 30 days of surgery with post-operative Health Care Associated Infection (HCAI). This will be defined by post-operative (> 72 hours) evidence of inflammation (fever, neutrophilia, C-Reactive Protein >100mg/L and infection (≥5 days prescription of antibiotic therapy) or bacteraemia with a recognised pathogen i.e., not a contaminant namely coagulase negative staphylococcus, Corynebacterium or Propionibacterium.
Surgical site infection
Superficial, deep and organ space surgical site infection. A wound assessment will be made at day 5 after operation and a questionnaire will be completed at day 30.
Microbiological evidence of urinary tract infection (UTI)
A urine sample with the detection of E.coli (or other Enterobacterales including Klebsiella, Enterobacter, Serratia, Citrobacter and Proteus)
Antimicrobial consumption after colorectal surgery
A day on which any antibiotic was consumed by a participant within 90 days of operations. Antibiotic prophylaxis e.g., for urinary tract infection, or splenectomy, are not included.
Antimicrobially resistant infections (AMR infections):
Infection with an antibiotic resistant bacteria will be identified by the rate of bacteraemia with the following antibiotic resistant bacteria detected in the blood stream: Methicillin resistant Staphylococcus aureus Vancomycin resistant Enterococcus faecalis/faecium Extended spectrum beta-lactamase (ESBL) E.coli (or other Enterobacterales including Klebsiella, Enterobacter, Serratia, Citrobacter and Proteus Carbapenemase producing Enterobacteriaceae (CPE) E.coli (or other Enterobacterales including Klebsiella, Enterobacter, Serratia, Citrobacter and Proteus)
C. difficile infection
A diagnosis of C. difficile infection (CDI) is one that requires confirmation of C. difficile toxin on a faeces test. Detection of the toxin gene by molecular testing is not sufficient. If multiple episodes if CDI infection, please report only the first episode
Anastomotic leakage after colorectal surgery
Radiological or surgical evidence of anastomotic leak
Mortality
Death
Length of hospital stay
The number of nights spend as a hospital in-patient within 90 days of operation.
Re-admission
Readmission to hospital following discharge with at least one night spent as a hospital in-patient.
Cost of healthcare treatment
Cost of healthcare treatment including days in hospital, surgical procedures and radiological procedures

Full Information

First Posted
November 1, 2022
Last Updated
September 6, 2023
Sponsor
University of Leeds
Collaborators
University of Birmingham, Aneurin Bevan University Health Board
search

1. Study Identification

Unique Protocol Identification Number
NCT05609240
Brief Title
Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery
Official Title
Colo-Pro_2: A Feasibility Randomised Controlled Double Blind Trial to Compare Standard Bolus Dosed Cefuroxime Prophylaxis to Bolus-continuous Infusion Dosed Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 10, 2023 (Actual)
Primary Completion Date
May 1, 2025 (Anticipated)
Study Completion Date
May 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Leeds
Collaborators
University of Birmingham, Aneurin Bevan University Health Board

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
After a surgical operation patients may have an infection in the operation wound, the bladder, kidneys or lungs. To stop these infections patients are given a dose of antibiotic before their operation. Unfortunately, the amount of antibiotic available to fight infections falls throughout an operation, being removed from the body by the kidneys. Therefore, antibiotic levels may not be high enough to stop infections. A way of maintaining antibiotic levels throughout an operation is to give a single dose of antibiotic and then a constant amount of antibiotic by an infusion from the start to the end of the operation. A small single centre test study was previosuly undertaken into antibiotic dosing during bowel operations. One group of patients had a single dose of antibiotic before their operation. The other group had a single dose plus a constant dose of antibiotic until the end of their operation. The project showed patients were happy to take part and that the study was safe. The study helped us identify the correct amounts of antibiotic needed for the patients given the single dose plus a constant dose of antibiotic. This study was conducted at one hospital only, and wasn't big enough to confirm if one treatment was better than another or if results would be similar in other hospitals. This study will build on the pilot study in a larger feasibility trial, the Colo-Pro_2 trial. It will be run in three hospitals so can assess if the trial design works at different hospitals. We will see if the results suggest one treatment, single dose of antibiotics before an operation, or single dose plus a constant dose of antibiotics throughout an operation, is better. This study will include up to 180 patients having bowel operations as they have a high risk of infection. All patients will be given the same antibiotic which is called cefuroxime. Cefuroxime is already used to stop infections after surgery. Using the same antibiotic in all patients means it is possible to know if differences in the number of infections are due to how the antibiotic is given. The number of infections that happen up to 30 days after operations will be counted. Staff looking after patients after the operation and those counting the infections will not know, unless necessary, the treatment patients received. This means the results won't be influenced by knowledge of the treatment received.
Detailed Description
See attached protocol

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Antibiotic Prophylaxis, Colorectal Surgery
Keywords
Cefuroxime, Antibiotic, Colorectal, Prophylaxis, Surgery

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
An anaesthetist will provide the intra-operative intervention and will the subsequently not be involved in the patients follow up or outcome assessment. alternatively, a research nurse not involved in participant follow up will provide the intra-operative intervention.
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard treatment
Arm Type
Active Comparator
Arm Description
Cefuroxime 1.5 grams intravenous Administered in the hour before surgery and then 4 hourly intra-operatively.
Arm Title
Intervention treatment
Arm Type
Active Comparator
Arm Description
Cefuroxime loading dose of 2332mg intravenous Administered in the hour before surgery. Following the loading dose a renal function based dosing will be given as a continuous intravenous infusion throughout surgery, as below. Continuous infusion will continue for up to 6 hours when it will return to 4 hourly dosing of cefuroxime at 1.5 grams intravenously, if required. Creatinine clearance (ml/min) and Cefuroxime:Dose per hour (mg/hr) 40-50ml/min=723mg/hr 50-60ml/min=867mg/hr 60-70ml/min=1011mg/hr 70-80ml/min=1155mg/hr >80ml/min=1227mg/hr
Intervention Type
Drug
Intervention Name(s)
Cefuroxime
Other Intervention Name(s)
Cefuroxime sodium for injection
Intervention Description
See arm/group description
Primary Outcome Measure Information:
Title
Recruitment rates
Description
Rate of recruitment
Time Frame
24 months
Title
Retention rates
Description
Rate of retention
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Health Care Associated Infection
Description
The number of patients within 30 days of surgery with post-operative Health Care Associated Infection (HCAI). This will be defined by post-operative (> 72 hours) evidence of inflammation (fever, neutrophilia, C-Reactive Protein >100mg/L and infection (≥5 days prescription of antibiotic therapy) or bacteraemia with a recognised pathogen i.e., not a contaminant namely coagulase negative staphylococcus, Corynebacterium or Propionibacterium.
Time Frame
30 days
Title
Surgical site infection
Description
Superficial, deep and organ space surgical site infection. A wound assessment will be made at day 5 after operation and a questionnaire will be completed at day 30.
Time Frame
30 days
Title
Microbiological evidence of urinary tract infection (UTI)
Description
A urine sample with the detection of E.coli (or other Enterobacterales including Klebsiella, Enterobacter, Serratia, Citrobacter and Proteus)
Time Frame
30 days
Title
Antimicrobial consumption after colorectal surgery
Description
A day on which any antibiotic was consumed by a participant within 90 days of operations. Antibiotic prophylaxis e.g., for urinary tract infection, or splenectomy, are not included.
Time Frame
90 days
Title
Antimicrobially resistant infections (AMR infections):
Description
Infection with an antibiotic resistant bacteria will be identified by the rate of bacteraemia with the following antibiotic resistant bacteria detected in the blood stream: Methicillin resistant Staphylococcus aureus Vancomycin resistant Enterococcus faecalis/faecium Extended spectrum beta-lactamase (ESBL) E.coli (or other Enterobacterales including Klebsiella, Enterobacter, Serratia, Citrobacter and Proteus Carbapenemase producing Enterobacteriaceae (CPE) E.coli (or other Enterobacterales including Klebsiella, Enterobacter, Serratia, Citrobacter and Proteus)
Time Frame
90 days
Title
C. difficile infection
Description
A diagnosis of C. difficile infection (CDI) is one that requires confirmation of C. difficile toxin on a faeces test. Detection of the toxin gene by molecular testing is not sufficient. If multiple episodes if CDI infection, please report only the first episode
Time Frame
90 days
Title
Anastomotic leakage after colorectal surgery
Description
Radiological or surgical evidence of anastomotic leak
Time Frame
90 days
Title
Mortality
Description
Death
Time Frame
90 days
Title
Length of hospital stay
Description
The number of nights spend as a hospital in-patient within 90 days of operation.
Time Frame
90 days
Title
Re-admission
Description
Readmission to hospital following discharge with at least one night spent as a hospital in-patient.
Time Frame
90 days
Title
Cost of healthcare treatment
Description
Cost of healthcare treatment including days in hospital, surgical procedures and radiological procedures
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Undergoing elective colorectal surgery (incision, excision or anastomosis of the large bowel, including anastomosis of small to large bowel) Age >16. Expected duration of surgery > 2hours Creatinine clearance > 40 ml/min Cefuroxime/metronidazole are appropriate antibiotic prophylaxis regimens. Patient capable of giving informed consent Patients undergoing colorectal surgery plus additional surgery e.g. plastic surgery, urological surgery, gynaecological surgery. Exclusion Criteria: Unable to consent Pregnancy Expected duration of surgery <2hours Creatinine clearance <40ml/min Individual level microbiological advice for non-cefuroxime based prophylaxis Cephalosporin allergy Penicillin allergy (hypersensitivity reaction only) Coumarin (warfarin and acenocoumarol) treatment Seizure history or epilepsy Concurrent use of probenecid Current participation in a research project aimed at reducing surgical site infections (SSIs) Antibiotics for treatment of a systemic Gram negative infection within 12 hours of initiation of surgery (Vancomycin, Teicoplanin, Daptomycin, Linezolid, Flucloxacillin. Nitrofurantoin and Clarithromycin would be permissible antibiotics without systemic Gram negative antibiotics). A current diagnosis of infection at the time of study entry. STARR procedures (stapled trans anal resection of the rectum) Weight <30kg or >110kg
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrew Kirby
Phone
01133923929
Email
a.kirby@leeds.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Dermot Burke
Phone
0113 3923465
Email
d.burke@leeds.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Kirby
Organizational Affiliation
The Univeristy of Leeds
Official's Role
Study Chair
Facility Information:
Facility Name
TheUniversity of Birmingham
City
Birmingham
State/Province
West Midlands
ZIP/Postal Code
B15 2TT
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Pinkney, MBChB
Email
t.pinkney@bham.ac.uk
Facility Name
Leeds Teaching Hospitals
City
Leeds
State/Province
West Yorkshire
ZIP/Postal Code
LS17 9EJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Kirby, MBChB
Phone
0113 3923929
Email
a.kirby@leeds.ac.uk
First Name & Middle Initial & Last Name & Degree
Dermot Burke, MBChB
Phone
0113 392 3465
Email
d.burke@leeds.ac.uk
Facility Name
Aneurin Bevan University Health Board
City
Newport
ZIP/Postal Code
NP20 2UB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tamas Szakmay, MBChB
Email
Tamas Szakmany <szakmanyt1@cardiff.ac.uk>

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery

We'll reach out to this number within 24 hrs